The lung cancer pathway is a multidisciplinary, transmural cancer care pathway that automatically collects the ICHOM lung cancer clinical indicators, helps the care team to coordinate care delivery, closely follows up on patients and ensures GPs are informed throughout the care process.
The pathway was created in an effort to improve quality of life for the patient, turn patients into active participants, increase involvement from the GP from diagnosis, detect adverse events and treatment side effects early, improve treatment decisions in a multidisciplinary team, optimize supportive care and introduce dedicated support around the end of life in a timely manner.
Patients are considered active participants and receive weekly action items such as going to the GP for a blood lab. GPs in turn are informed about the progress of the patients in the pathway thanks to automated progress notes sent to the GPs electronic medical record system.
The care team exists of nurse coordinators, psychologists, social workers, palliative nurses, oncologists and other supporting caregivers. Each profile is alerted specifically when a patient reports moderate or severe side effects. Care delivery in the pathway is standardized across all available treatment modalities, and 100% of the patients diagnosed with lung cancer can be included in the pathway, also those not on an active treatment.
From diagnosis to 10 years after treatment
- Standardized breast cancer pathway variations
- ICHOM breast cancer standard set
- DICA breast cancer indicator set
- Weekly PRO-CTCAE questionnaire to monitor side effects before, during and right after treatment
- Alerts to the relevant caregivers when side effects occur
- Dynamic tips on how to self-manage side effects sent to patients
- Information brochures about breast cancer, therapies, catheter, etc
- PREMs questionnaire (Mammacare)